SCHEMBL18263252

SCHEMBL18263252

CC(C)(C)OC(=O)N1CCC2(CCC(N)C2)CC1

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 9/20 0.47
HPGD P15428 1/20 0.44
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
EPHX2 P34913 1/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
KDM1A O60341 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
NAMPT P43490 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24588839 0.92 GPR119 (0.43) GPR119HPGDUSP2SMN1; SMN2EPHX2
SCHEMBL16054753 0.91 GPR119 (0.49) GPR119HPGDUSP2SMN1; SMN2EPHX2
SCHEMBL623537 0.89 GPR119 (0.50) GPR119HPGDUSP2SMN1; SMN2EPHX2
SCHEMBL30901515 0.87 HPGD (0.39) GPR119HPGDUSP2SMN1; SMN2EPHX2
SCHEMBL23228620 0.87 HPGD (0.39) GPR119HPGDUSP2SMN1; SMN2EPHX2
Hydrochloric Acid SCHEMBL29691280 0.85 HPGD (0.38) GPR119HPGDUSP2SMN1; SMN2EPHX2
SCHEMBL17107663 0.85 CYP11B2 (0.47) GPR119HPGDUSP2SMN1; SMN2RECQL
SCHEMBL9994757 0.84 CYP11B2 (0.46) GPR119USP2SMN1; SMN2EPHX2
SCHEMBL24753361 0.84 HPGD (0.49) GPR119HPGDUSP2SMN1; SMN2EPHX2
SCHEMBL20461030 0.84 HPGD (0.49) GPR119HPGDUSP2SMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096858-A1 COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
EP-4351583-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 Therapeutics, Inc. (US) 2024-04-17 EP disclosed
WO-2022261250-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2022-12-15 WO disclosed
WO-2022261250-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2022-12-15 WO disclosed
WO-2016190847-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2016-12-01 WO disclosed